Business Wire

AgroAmerica Supports the Conservation of Scarlet Macaws in the Mayan Biosphere of Guatemala

Share

Recently, 26 scarlet macaws were freed in Guatemala's Maya Biosphere Reserve with the support of AgroAmérica, Wildlife Conservation Society (WCS), Fundación Solidaridad Latinoamericana, and the National Council of Protected Areas (CONAP, by its Spanish acronym).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201103005302/en/

Picture by WCS Guatemala - Release of 26 Young Scarlet Macaws into Guatemala's Maya Biosphere Reserve. The release was carried out thanks to the joint effort of AgroAmerica, Wildlife Conservation Society (WCS), Fundación Solidaridad Latinoamericana, and the National Council of Protected Areas of Guatemala. (Photo: Business Wire)

Picture by WCS Guatemala - Release of 26 Young Scarlet Macaws into Guatemala's Maya Biosphere Reserve. The release was carried out thanks to the joint effort of AgroAmerica, Wildlife Conservation Society (WCS), Fundación Solidaridad Latinoamericana, and the National Council of Protected Areas of Guatemala. (Photo: Business Wire)

This was done with the purpose of increasing the number of these specimens in the Maya Biosphere Reserve and, therefore, contributing to the strengthening of the wild population of scarlet macaws. After their release it is estimated that there are about 300 macaws in the reserve.

"Macaws are increasingly threatened by poaching for the illegal wildlife trade, in addition to habitat loss, driven largely by intentional forest fires, livestock and the expansion of human settlements," WCS reported.

"At AgroAmerica, we are fully committed to supporting activities to protect and maintain riparian zones in the areas in where we conduct agricultural operations, and in areas of biological importance for the country," Fernando Bolaños, CEO of AgroAmérica, said.

To fulfill this commitment, the agro-industrial food company, AgroAmérica, signed an agreement with WCS and Fundación Solidaridad to strengthen the Guatemalan System of Protected Areas (SIGAP, by its Spanish acronym) through the implementation of pilot projects to restore and maintain the landscape, according to the strategies of CONAP and the Ministry of Environment and Natural Resources (MARN by its Spanish acronym).

The agreement seeks to support the conservation of 19,000 hectares of forest at Laguna del Tigre National Park. This is to help protect and monitor endangered species and their habitats, including animals such as scarlet macaws, jaguars, white-lipped peccaries, tapirs and white turtles. This will assist us in maintaining natural ecosystems (forests, wetlands and savannas) protected from threats like fires, invasions and other illegal activities in the ecosystems of the project area.

AgroAmérica also joined the environmental conservation project of the Foundation of Cultural and Natural Maya Patrimony (PACUNAM, by its Spanish acronym) to contribute to the protection of the cultural and natural heritage, such as the tropical forest and the flora and fauna of the Maya Biosphere Reserve in Guatemala.

"At AgroAmerica we implement a Zero Deforestation policy, we share good practices and field experiences related to the RSPO standard; we actively participate in technical roundtables that seek to manage and develop sustainable landscapes and we support specific reforestation and conservation projects," Bolaños stated.

The freeing of macaws is one of the many projects promoted by AgroAmérica.

About AgroAmérica

AgroAmérica is an agro-industrial company dedicated to the production and commercialization of food products, through the use of sustainable and responsible cultivation methods. Our company has operations in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama. AgroAmérica operates on the basis of a corporate sustainability strategy to generate value and balance between economic growth, natural resource conservation and the well-being of its customers and stakeholders.

Contact information

Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
(502) 2420-9600

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 19:36:00 EETPress release

Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological

Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 19:00:00 EETPress release

Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond

WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 18:46:00 EETPress release

WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said: “ We are

PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 17:16:00 EETPress release

In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac

Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 15:17:00 EETPress release

The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 14:00:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance

Janssen Submits Marketing Authorisation Extension to the European Medicines Agency to Register Paliperidone Palmitate 6-Monthly (PP6M) for Treatment of Schizophrenia in Adults4.12.2020 12:01:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Marketing Authorisation Extension Application to the European Medicines Agency (EMA) to register paliperidone palmitate 6-monthly (PP6M) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on paliperidone palmitate 1‑monthly (PP1M)1 or 3-monthly (PP3M)2 injectable products. If approved, this long‑acting injectable will provide adults living with schizophrenia a twice-yearly dosing regimen, the longest dosing interval available for an antipsychotic medication in the European Economic Area.3 “Janssen’s roots in neuroscience began with research and development of novel therapeutic options for schizophrenia, and this filing builds on that 60-year commitment,” said Bill Martin, Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC. “We designed this unique dosing regimen so people with schizophrenia and their healthcare team can focus less on medication inte

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom